The Iran conflict is disrupting the World Health Organization’s (WHO) emergency medical supply network, particularly shipments moving through its primary logistics hub in Dubai, as reported by Reuters. As a result, WHO has been forced to reroute supplies along longer, more complex overland corridors through Saudi Arabia, Jordan, and Syria, which is slowing deliveries to crisis zones such as Lebanon and creating significant logistical bottlenecks.
Transport costs have climbed roughly 30%, driven largely by rising fuel prices and inefficient routing. Lead times are extending, shipment backlogs are growing, and WHO is increasingly reliant on ground transport and external support, including assistance from the UAE, to maintain supply continuity.
Beyond humanitarian logistics, the conflict is also placing new pressure on the global pharmaceutical supply chain. Disruptions to key transit routes, including airspace restrictions and maritime chokepoints like the Strait of Hormuz, are slowing the movement of active pharmaceutical ingredients (APIs) and finished drugs. While manufacturing capacity remains largely intact, the ability to move products efficiently is becoming the primary risk factor, driving up costs and increasing the potential for delays across global distribution networks.
The disruption highlights the fragility of global health supply chains, particularly those dependent on centralized hubs and stable trade routes. Longer pathways, higher costs, and geopolitical volatility are converging into a real-time stress test, not just for emergency response systems but for the broader pharmaceutical supply chain worldwide.
